Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Sells 251,844 Shares of Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd sold 251,844 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $9.10, for a total value of $2,291,780.40. Following the sale, the insider directly owned 5,187,156 shares of the company’s stock, valued at approximately $47,203,119.60. This represents a 4.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total value of $3,495,079.50.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total value of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.
• On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.15, for a total value of $396,994.65.
• On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.04, for a total value of $1,250,260.20.
• On Thursday, July 30th, L1 Capital Pty Ltd sold 558,633 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.20, for a total transaction of $4,580,790.60.
• On Monday, July 27th, L1 Capital Pty Ltd sold 232,817 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.19, for a total transaction of $1,906,771.23.
• On Tuesday, July 28th, L1 Capital Pty Ltd sold 208,731 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.09, for a total transaction of $1,688,633.79.

Anteris Technologies Global Stock Performance

Shares of Anteris Technologies Global stock opened at $8.87 on Thursday. The company has a market cap of $863.42 million, a P/E ratio of -4.55 and a beta of 1.78. Anteris Technologies Global Corp. has a one year low of $3.30 and a one year high of $11.06. The firm has a fifty day moving average of $9.15 and a two-hundred day moving average of $7.35.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The firm had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 110.36%. During the same period in the previous year, the firm earned ($0.58) EPS. As a group, equities analysts predict that Anteris Technologies Global Corp. will post -1.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Friday, May 29th. Wall Street Zen raised Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Barclays raised their price target on Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Key Headlines Impacting Anteris Technologies Global

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Q2 loss narrowed and sales increased: Anteris reported a second-quarter 2026 loss of $0.30 per share, an improvement from the $0.58 loss recorded a year earlier. Net sales rose to $1.01 million, although the figure remained below the $1.50 million analyst estimate. Anteris Technologies Q2 Loss Narrows, Net Sales Rise
• Positive Sentiment: Medicare reimbursement eligibility supports the clinical program: The company said eligible U.S. sites in its global pivotal PARADIGM trial can receive Medicare reimbursement under a Centers for Medicare & Medicaid Services national coverage policy. This could improve trial execution and reduce financial barriers to participation. Anteris Technologies Announces Results for the Second Quarter of 2026
• Neutral Sentiment: Development-stage profile remains central to the outlook: Anteris continues investing heavily in medical-device development, reflected in its extremely negative net margin and negative return on equity. Investors are likely focused on clinical milestones, commercialization prospects and future funding needs rather than near-term profitability.
• Negative Sentiment: Quarterly results missed expectations: The $0.30-per-share loss was wider than the consensus estimate of $0.21, while revenue also fell short of expectations. The earnings miss can weigh on the stock despite year-over-year improvement. Anteris Technologies Global earnings report
• Negative Sentiment: Major shareholder continues reducing its position: L1 Capital Pty Ltd disclosed sales of 375,815 shares on August 11 and 251,844 shares on August 10, following earlier sales including 174,721 shares on August 6. The repeated selling, totaling more than 800,000 shares across these disclosures, creates additional supply and may signal reduced conviction or portfolio rebalancing. SEC filing on L1 Capital share sales

Hedge Funds Weigh In On Anteris Technologies Global

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its stake in shares of Anteris Technologies Global by 76.9% in the third quarter. Russell Investments Group Ltd. now owns 6,536 shares of the company’s stock valued at $29,000 after purchasing an additional 2,841 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Anteris Technologies Global during the first quarter worth about $32,000. BNP Paribas Financial Markets grew its position in Anteris Technologies Global by 83.3% during the third quarter. BNP Paribas Financial Markets now owns 9,469 shares of the company’s stock worth $43,000 after buying an additional 4,302 shares during the period. Bank of America Corp DE boosted its stake in shares of Anteris Technologies Global by 35.7% during the 3rd quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock worth $48,000 after acquiring an additional 2,798 shares in the last quarter. Finally, Duncan Williams Asset Management LLC purchased a new stake in shares of Anteris Technologies Global during the 4th quarter worth approximately $54,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.